Navigating Second-Line Treatment After EV+P: Insights from a Survey of Urothelial Cancer Experts

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, a group of four experts weigh in on their survey-based study of treatment sequencing after first-line enfortumab vedotin/pembrolizumab in the evolving landscape of locally advanced/metastatic urothelial cancer.

Sharing their insights are Priyanka Chablani, MD, MS; Ali R. Khaki, MD; Karine Tawagi, MD; and Petros Grivas, MD, PhD.